Roche Expands Alzheimer’s Pipeline With New Phase II TARBELA-AD Trial Of Oral NLRP3 Inhibitor RG6434, To Present Trontinemab, PrevenTRON, Elecsys Blood Test Data At CTAD November 16-19

Benzinga
Abrir em Benzinga